Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen

Endocr Relat Cancer. 2022 Nov 7;29(12):717-733. doi: 10.1530/ERC-22-0108. Print 2022 Dec 1.

Abstract

Prostate cancer research suffers from the lack of suitable models to study the role of normal cells in prostate carcinogenesis. To address this challenge, we developed a cell line model mimicking luminal prostate epithelial cells by modifying the immortalized prostate epithelial cell line RWPE-1 to constitutively express the androgen receptor (AR). RWPE-1-AR cells express known AR target genes, and exhibit coexpression of luminal and basal markers characteristic of transient amplifying cells, and an RNA signature resembling prostate luminal progenitor cells. Under unstimulated conditions, constitutive AR expression does not have a biologically significant effect on the proliferation of RWPE-1 cells, but when stimulated by androgens, growth is retarded. The transcriptional response of RWPE-1-AR cells to androgen stimulation involves suppression of the growth-related KRAS pathway and is thus markedly different from that of the prostate cancer cell line LNCaP and its derivative AR-overexpressing LNCaP-ARhi cells, in which growth- and cancer-related pathways are upregulated. Hence, the nonmalignant AR-positive RWPE-1-AR cell line model could be used to study the transformation of the prostate epithelium.

Keywords: androgen receptor; androgen response; cell models; prostate cancer; prostate epithelium.

MeSH terms

  • Androgens / metabolism
  • Cell Line
  • Cell Line, Tumor
  • Epithelial Cells / metabolism
  • Humans
  • Male
  • Prostate* / metabolism
  • Prostatic Neoplasms* / metabolism
  • Receptors, Androgen / metabolism

Substances

  • Androgens
  • Receptors, Androgen